Amphion Innovations PLC Additional Draw on Loan Facility (9883G)
November 26 2015 - 2:00AM
UK Regulatory
TIDMAMP
RNS Number : 9883G
Amphion Innovations PLC
26 November 2015
Amphion Innovations plc
("Amphion" or "the Company")
Additional Draw on Loan Facility
London and New York, 26 November 2015 - Amphion Innovations plc
(LSE: AMP), the developer of medical, life science, and technology
businesses, today announces that the Company has agreed terms for
the draw-down of an additional tranche of US $3 million under the
loan facility as announced on 5 June 2014 ("Facility") to be
drawn-down in two consecutive tranches ("Additional Draw"), the
first being made on 25 November 2015 and the second on 8 December
2015.
Under the terms of the Additional Draw, the simulated warrants
over Kromek Group plc, as detailed in the 5 June 2014 announcement,
will be canceled, the interest rate on the Facility will be reduced
from 12% to 10%, and no additional Amphion warrants will be
granted. The remaining terms of the Additional Draw is on
substantially the same terms as the Facility.
The Additional Draw is to be repaid in monthly installments
starting 1 March 2016, with the final monthly repayment due on 1
November 2016. The proceeds are to be used to repay the existing
amount due under the Facility and for working capital for Amphion
and its Partner Companies.
For further information please contact:
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Yellow Jersey PR
Charles Goodwin / Dominic Barretto
+44 (0)7747 788 221
Panmure Gordon Limited (Nominated Adviser and Corporate
Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)
Stephen Austin
+44 (0)20 7183 2493
+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUVUBRVNAAUAA
(END) Dow Jones Newswires
November 26, 2015 02:00 ET (07:00 GMT)
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2023 to Apr 2024